Exploring Exon 20 Insertion Mutations in Non−Small Cell Lung Cancer: New Drug Therapies and Treatment Optimization Strategies for Oncology Pharmacists

Exploring Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer: New Drug Therapies and Treatment Optimization Strategies for Oncology Pharmacists is organized by Pharmacy Times Continuing Education (PTCE).,Release date: May 17, 2022,Expiration date: May 17, 2023,Description:,Lung cancer is the most commonly diagnosed cancer and a leading cause of cancer deaths in the United States. Non-small cell lung cancer (NSCLC) associated with exon 20 insertion mutations occurs in approximately 10% of epidermal growth factor receptor (EGFR) mutations and is often resistant to conventional EGFR tyrosine kinase inhibitors. Until recently, there were no targeted therapies available specifically for patients with exon 20 insertion mutations. This activity will review data supporting the use of these new therapies as well as their place in treatment for patients with exon 20 EGFR-positive NSCLC. This program also features video animations detailing the relationship between disease pathophysiology and the mechanism of action of the therapies. Considerations for oncology pharmacists surrounding biomarker testing, drug interactions, and managing adverse effects to optimize patient care will also be discussed.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Distinguish epidermal growth factor receptor (EGFR) exon 20 insertion mutations based on pathobiology, prevalence, prognosis, and general treatment strategies,• Explore the pharmacology of novel drugs targeting EGFR exon 20 insertion mutations and their place in the current treatment paradigm,• Investigate opportunities to improve patient outcomes through pharmacist interventions and mitigating toxicities